Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7

Vaccine

Volumn 18, Issue 25, 2000, Pages 2886-2894

  Kim, Tae S ^a   Chung, Su W ^a   Hwang, Seung Y ^b  

^a Chonnam National University   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

B7.1; Cytotoxic T lymphocyte; Fibroblast vaccine; Gene therapy; Interleukin 7

Indexed keywords

B7 ANTIGEN; INTERLEUKIN 7; OVALBUMIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA TRANSFECTION; FEMALE; FIBROBLAST; GENETIC ENGINEERING; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034660360     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00061-X     Document Type: Article

References (37)

1. Schuler G., Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumor. J. Exp. Med. 186:1997;1183-1187.
2. Restifo N.P., Kawakami Y., Marincola F., et al. Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J. Immunother. 14:1993;182-190.
3. + T cells by B7-transfected melanoma cells. Science. 259:1993;368-370.
4. Lefor A.T., Fabian D.F. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model. J. Surg. Res. 75:1998;49-53.
5. Bubenik J. Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol. Ther. 69:1996;1-14.
6. Ni K., O'Neill H.C. The role of dendritic cells in T cell activation. Immunol. Cell Biol. 75:1997;223-230.
7. Sorg R.V., McLellan A.D., Hock B.D., Fearnley D.B., Hart D.N. Human dendritic cells express functional interleukin-7. Immunobiology. 198:1998;514-526.
8. Boon T., Cerottini J.C., Van den Eynde B., Van der Bruggen P., Van Pel A. Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol. 12:1994;337-365.
9. Kawakami Y., Rosenberg S.A. Human tumor antigens recognized by T-cells. Immunol. Res. 16:1997;313-339.
10. Disis M.L., Grabstein K.H., Sleath P.R., Cheever M.A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5:1999;1289-1297.
11. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T., Falo L.D. Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:1996;283-287.
12. Hsu F.J., Benike C., Fagnoni F., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:1996;52-58.
13. Timmerman J.M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Ann. Rev. Med. 50:1999;507-529.
14. Kim T.S., Cohen E.P. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res. 54:1994;2531-2535.
15. Tahara H., Zeh H.J., Storkus W.J., et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:1994;182-189.
16. Kim T.S., Xu W.S., Sun T., Cohen E.P. Treatment with interleukin-2/interferon-γ double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma. Melanoma Res. 5:1995;217-227.
17. Sigal L.J., Reiser H., Rock K.L. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo. J. Immunol. 161:1998;2740-2745.
18. Daniel P.T., Kroidl A., Cayeux S., Bargou R., Blankenstein T., Dorken B. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J. Immunol. 159:1997;3808-3815.
19. Appasamy P.M. Interleukin-7: biology and potential clinical applications. Cancer Invest. 11:1993;487-499.
20. Alderson M.R., Sassenfeld H.M., Widmer M.B. Interleukin 7 enhances cytotoxic T-lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J. Exp. Med. 172:1990;577-587.
21. Aoki T., Tashiro K., Miyatake S., et al. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA. 89:1992;3850-3854.
22. McBride W.H., Thacker J.D., Comora S., et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulate host cell infiltration and tumor immunity. Cancer Res. 52:1992;3931-3937.
23. Kawashima I., Tsai V., Southwood S., Takesako K., Sette A., Celis E. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 59:1999;431-435.
24. Sudo T., Ito M., Ogawa Y., et al. Interleukin 7 production and function in stromal cell-dependent B cell development. J. Exp. Med. 170:1989;333-338.
25. Kim T.S., Collins M.K.L., Russell S.J., Cohen E.P. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of tumor-bearing mice. Int. J. Cancer. 55:1993;865-872.
26. Kang B.Y., Lim Y.S., Chung S.W., et al. Antigen-specific cytotoxicity and cell number of adoptively transferred T cells are efficiently maintained in vivo by restimulation with an antigen/interleukin-2 fusion protein. Int. J. Cancer. 82:1999;569-573.
27. Fearon E.R., Pardoll D.M., Itaya T., et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 60:1990;397-403.
28. Kim T.S., Cohen E.P. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells. J. Immunother. 16:1994;24-35.
29. Chen S.H., Chen X.H., Wang Y., et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA. 92:1995;2577-2581.
30. Wakimoto H., Abe J., Tsunoda R., Aoyagi M., Hirakawa K., Hamada H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res. 56:1996;1828-1833.
31. Addison C.L., Bramson J.L., Hitt M.M., Muller W.J., Gauldie J., Graham F.L. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Therapy. 5:1998;1400-1409.
32. Rosenthal F.M., Cronin K., Bannerji R., Golde D.W., Gansbacher B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs. Blood. 83:1994;1289-1298.
33. Cayeux S., Beck C., Aicher A., Dorken B., Blankenstein T. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol. 25:1995;2325-2331.
34. Cayeux S., Richter G., Noffz G., Dorken B., Blankenstein T. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol. 158:1997;2834-2841.
35. Kato K., Okumura K., Yagita H. Immunoregulation by B7 and IL-12 gene transfer. Leukemia. 11:1997;572-576.
36. Yang S., Vervaert C.E., Seigler H.F., Darrow T.L. Tumor cells cotransduced with B7.1 and IFN-γ induce effective rejection of established parental tumor. Gene Therapy. 6:1999;253-262.
37. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Ann. Rev. Immunol. 14:1996;233-258.